How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Baylor College of Medicine
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine